bit.bio announces the first close of their Series B financing of $103 million. New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent. The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. Source: bit.bio press release 5/11/2021